Medical radiotheranostics, a revolutionary concept in cancer care, integrates diagnosis and therapy, enhancing the precision and efficacy of treatments. This innovative approach utilises radiolabelled compounds that can both image and treat malignancies, offering a dual benefit that has significantly advanced the field of nuclear medicine.
The term ‘radiotheranostics’ combines ‘radiotherapy’ and ‘diagnostics’, reflecting its dual functionality. It involves the use of specific molecules that bind to cancer cells and are tagged with radioactive isotopes. These isotopes are carefully chosen so that their emitted radiation can be detected by imaging techniques such as Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT), allowing for precise tumour localisation. Following imaging, the same radioactive isotopes deliver targeted radiation therapy, destroying the cancer cells while minimising damage to surrounding healthy tissue.
One of the pivotal elements of radiotheranostics is the selection of appropriate targets on cancer cells, such as receptors or antigens that are overexpressed in certain tumour types. For example, the prostate-specific membrane antigen (PSMA) is used as a target in prostate cancer. Radiolabelled molecules that bind to PSMA can be visualised to assess the extent and location of the cancer and then used to deliver lethal doses of radiation directly to the tumour cells.
This targeted approach offers several advantages over traditional methods. Firstly, it allows for the assessment of the biodistribution of the radiopharmaceutical, ensuring that it accumulates sufficiently within the tumour before commencing therapeutic radiation. This leads to a more tailored treatment plan based on the individual’s specific disease presentation, which can result in improved efficacy and reduced side effects. Additionally, radiotheranostics can provide vital information on tumour response early in the treatment course, enabling adjustments to be made if necessary.
Another significant benefit of radiotheranostics is its potential in treating metastatic diseases, which are often difficult to manage with conventional therapies. For instance, Lutetium-177 PSMA therapy has shown promising results in patients with metastatic castration-resistant prostate cancer, providing a new lifeline where previous therapies have failed.
The future of medical radiotheranostics looks promising as research continues to evolve. New targets are being explored, and advances in molecular biology and imaging technology are likely to expand the range of cancers that can be treated with this method. Moreover, developing novel radiolabelled compounds that can be used for diagnostic and therapeutic purposes is set further to enhance the effectiveness and safety of cancer treatments, heralding a new era in personalised medicine. As this field grows, it holds the potential to significantly alter the landscape of cancer treatment, offering hope to those battling this complex disease.
You are here:
home »
By | 9 minutes of readingYttrium-90 Tabituximab barzuxetan is a radiolabelled drug designed for targeted synovial sarcoma treatment.
By | 10 minutes of readingYttrium-90 OPS201, a receptor antagonist, delivers targeted beta radiation for effective neuroendocrine tumour therapy and research.
Yttrium-90 OPS201: A Potential Breakthrough in Neuroendocrine Tumour Therapy Read Post »
By | 10 minutes of readingZevalin therapy combines monoclonal antibody targeting with Yttrium-90 radiation to treat non-Hodgkin’s lymphoma effectively.
By | 10 minutes of readingFerritarg therapy targets acidic ferritin in cancer cells, offering precision treatment for refractory Hodgkin’s disease and other malignancies.
Ferritarg: A Multifaceted Antibody Approach for Targeted Cancer Therapy Read Post »
By | 9 minutes of readingYttrium-90 FAPi-46 targets fibroblast activation protein, providing effective radiotherapy for tumours and fibrotic diseases.
By | 8 minutes of readingYttrium-90 FAPi-04 is a promising radiotherapeutic targeting fibroblast activation protein in cancer-associated fibroblasts effectively.
Yttrium-90 FAPi-04: A Novel Radiotherapeutic Targeting Fibroblast Activation Protein Read Post »
By | 9 minutes of readingYttrium-90 Epratuzumab Tetraxetan enhances Non-Hodgkin Lymphoma treatment through targeted radioimmunotherapy and durable responses.
By | 10 minutes of readingYttrium-90 Edotreotide delivers targeted beta radiation therapy to somatostatin receptor-positive neuroendocrine tumours with precision.
By | 10 minutes of readingYttrium-90 DOTA-FF-21101 targets P-Cadherin in solid tumours, delivering beta radiation for precise cancer treatment.
By | 10 minutes of readingYttrium-90 Besilesomab targets CD66-expressing cells, providing precise beta radiation therapy for systemic amyloid light chain amyloidosis.
By | 11 minutes of readingYttrium-90 Anditixafortide targets CXCR4-expressing tumours, delivering therapeutic β– radiation precisely, improving treatment outcomes significantly.
By | 12 minutes of readingRadioactive isotopes emit targeted radiation that effectively destroys cancer cells while minimising harm to healthy tissues.
Biological Principles Underpinning Targeted Radionuclide Therapy for Cancer Read Post »
By | 9 minutes of readingThorium-227 Anetumab Corixetan delivers targeted alpha radiation, effectively treating mesothelin-expressing tumours while sparing healthy tissues.
By | 12 minutes of readingTerbium-161 PSMA-I&T combines precise PSMA targeting with beta and Auger emissions, revolutionising prostate cancer treatment efficacy.
Terbium-161 PSMA-I&T: A New Frontier in Targeted Radioligand Therapy Read Post »
By | 10 minutes of readingTin-117m DTPA offers innovative treatment options for bone metastases, combining therapeutic efficacy with minimal collateral tissue damage.
By | 10 minutes of readingTin-117m DOTA-Annexin V revolutionises medicine by simultaneously imaging and treating vulnerable plaques, cancers, and neuroinflammation.
By | 12 minutes of readingSamarium-153 DOTMP, a promising radiopharmaceutical, targets bone metastases effectively while allowing precise imaging for clinical monitoring.
Samarium-153 DOTMP (CycloSAM): A Renaissance in Bone Pain Palliation Read Post »
By | 4 minutes of readingRhenium-188 SSS/Lipiodol combines targeted delivery with beta radiation, offering hope for advanced hepatocellular carcinoma patients.
By | 6 minutes of readingRhenium-188 Colloidal Sulfide provides targeted radiation therapy, reducing joint inflammation and pain in large rheumatoid arthritis-affected joints.
By | 13 minutes of readingRhenium-188 HDD/Lipiodol therapy offers targeted radiopharmaceutical treatment for advanced hepatocellular carcinoma with portal vein thrombosis.
By | 12 minutes of readingRhenium-188 P2045 is a peptide-based radiopharmaceutical targeting somatostatin receptors for treating neuroendocrine and pancreatic cancers.
By | 11 minutes of readingRhenium-188 Etidronate effectively targets metastatic bone lesions, delivering therapeutic beta radiation while reducing associated pain.
By | 12 minutes of readingRhenium-188 ImDendrim combines targeted nitro-imidazole ligands and dendrimers to deliver beta radiation to hypoxic tumours.
By | 11 minutes of readingLead-203 DOTA-VMT-MCR1 binds MC1R with high specificity, facilitating targeted imaging and image-guided therapy for metastatic melanoma patients.
By | 10 minutes of readingLead-212 VMT-α-NET offers advanced targeted therapy for neuroendocrine tumours by harnessing precise alpha-particle radiation.
By | 13 minutes of readingLead-212 DOTAMTATE targets somatostatin receptors in neuroendocrine tumours, delivering potent alpha-emission therapy with minimal off-target toxicity.
Lead-212 DOTAMTATE: A Novel Alpha-Emitting Therapy for Neuroendocrine Tumours Read Post »
By | 4 minutes of readingPhosphorus-32 Colloidal Chromic Phosphate delivers precise beta radiation for treating malignant effusions and cystic tumours.
By | 4 minutes of readingLutetium-177 XT033 combines PSMA targeting and Evans blue technology to improve metabolic stability and therapeutic effectiveness.
By | 3 minutes of readingLutetium-177 Vipivotide Tetraxetan is a groundbreaking radioligand therapy targeting PSMA, offering precise tumour treatment with minimal damage to healthy tissues.
Lutetium-177 Vipivotide Tetraxetan: A Breakthrough in Radioligand Therapy for mCRPC Read Post »
By | 4 minutes of readingLutetium-177 TLX250 targets CA-IX-expressing tumours, providing a selective radiotherapy approach for treating advanced renal cell carcinoma.
By | 4 minutes of readingLutetium-177 Satoreotide Tetratexan is a radiopharmaceutical targeting somatostatin receptors, providing advanced therapeutic options for neuroendocrine neoplasms effectively.
By | 7 minutes of readingLutetium-177 Rosopatamab is a radiopharmaceutical therapy combining targeted monoclonal antibodies with beta-emitting radioactive particles.
By | 6 minutes of readingLutetium-177 RM2 leverages GRPR targeting to deliver therapeutic beta radiation, minimising off-target effects and enhancing prostate cancer treatment outcomes.
Transforming Prostate Cancer Treatment: Exploring Lutetium-177 RM2 Read Post »
By | 4 minutes of readingLutetium-177 Rituximab offers a targeted radiopharmaceutical solution, delivering beta radiation to CD20-positive cells, ensuring effective and precise lymphoma therapy.
Lutetium-177 Rituximab: A Novel Radiopharmaceutical for Non-Hodgkin Lymphoma (NHL) Read Post »
By | 4 minutes of readingRhPSMA revolutionises prostate cancer management with dual labelling, enabling precise imaging and effective targeted radiotherapy options.
RhPSMA: A Dual-Labelling Radiohybrid for Prostate Cancer Diagnosis and Therapy Read Post »
By | 4 minutes of readingLutetium-177 PSMA-R2 is a urea-based therapeutic agent targeting PSMA, effectively treating advanced prostate cancer patients.
The Development of Lutetium-177 PSMA-R2: A Novel Therapeutic Agent for Prostate Cancer Read Post »
By | 4 minutes of readingLutetium-177 PSMA-ALB-56 is an innovative treatment optimising prostate cancer therapy through targeted radiopharmaceutical advancements.
Lutetium-177 PSMA-ALB-56: A Promising Radiopharmaceutical for Prostate Cancer Therapy Read Post »
By | 4 minutes of readingLutetium-177 PNT6555, a FAP-targeted radiopharmaceutical, combines precision therapy with beta radiation for tumour-specific treatment.
Lutetium-177 PNT6555: A Breakthrough in FAP-Targeted Radiopharmaceutical Therapy Read Post »
By | 4 minutes of readingLutetium-177 PNT2002 offers targeted radiotherapy for prostate cancer, combining precise tumour targeting with therapeutic and diagnostic capabilities.
Lutetium-177 PNT2002: A Promising PSMA-Targeted Radiopharmaceutical Read Post »
By | 4 minutes of readingLutetium-177 Pentixather targets CXCR4-expressing tumours, delivering precise beta radiation therapy to eliminate malignant cells effectively.
By | 15 minutes of readingLutetium-177 Oxodotreotide Treatment offers targeted neuroendocrine tumour therapy, improving progression-free survival and patient outcomes significantly.
Neuroendocrine Tumour Therapy with Cutting-Edge Lutetium-177 Oxodotreotide Innovation Read Post »
By | 10 minutes of readingLutetium-177 MVT-1075 radioimmunotherapy targets pancreatic cancer by utilising CA19-9 specificity, sialyl-Lewis a binding, and precision radiation delivery.
Lutetium-177 MVT-1075: A Breakthrough in Pancreatic Cancer Radioimmunotherapy Read Post »
By | 10 minutes of readingLutetium-177 Ludotadipep targets PSMA with enhanced stability, specificity, and reduced side-effects, revolutionising prostate cancer treatment.
By | 10 minutes of readingLutetium-177 LNC1010, a radiolabelled therapy, targets somatostatin receptors, delivering precise treatment with minimal side effects.
By | 4 minutes of readingA novel radiolabelled drug, Lutetium-177 LNC1004, targets fibroblast activation protein, transforming cancer therapy through precision and innovation.
By | 5 minutes of readingRadiopharmaceutical therapy in cancer offers targeted treatment, minimising side effects while enhancing patient outcomes.
Radiopharmaceutical Therapy in Cancer: A Beacon of Hope in Oncology Read Post »
By | 4 minutes of readingBetalutin combines the precision of CD37-targeting antibody Lilotomab with Lutetium-177, offering targeted and effective haematological cancer treatment.
Betalutin: A Revolutionary Therapeutic Pathway in Haematological Cancer Treatment Read Post »
By | 4 minutes of readingTargeting glioblastoma with Lutetium-177 ITM-31 offers precise intracavitary treatment, reducing recurrence by specifically addressing residual cancer cells post-surgery.
Targeting Glioblastoma with Precision: The Promise of Lutetium-177 ITM-31 Read Post »
By | 5 minutes of readingLutetium-177 iPSMA revolutionises prostate cancer treatment, delivering targeted beta radiation to metastatic cells with precision and minimal side effects.
Lutetium-177 iPSMA: A Game-Changer in Prostate Cancer Therapy Read Post »
By | 5 minutes of readingTargeting Neurotensin Receptor-1 with Lutetium-177 IPN-01087 demonstrates promising precision therapy, delivering beta radiation for treating invasive cancers like ductal pancreatic adenocarcinoma.
Targeting Neurotensin Receptor-1: Lutetium-177 IPN-01087 in Oncology Read Post »
By | 4 minutes of readingAdvancing prostate cancer treatment, Lutetium-177 HTK03170 and Gallium-68 HTK03149 enable targeted PSMA therapy, improving diagnosis and therapeutic outcomes.
By | 4 minutes of readingLutetium-177 FAPI-04 revolutionises cancer treatment by precisely targeting cancer-associated fibroblasts, enabling dual imaging and radiotherapy functionalities for enhanced outcomes.
Innovative Radiotherapeutics: Lutetium-177 FAPI-04 as a Game-Changer in Cancer Treatment Read Post »
By | 4 minutes of readingRevolutionising cancer therapy, Lutetium-177 FAP-2286 offers precise diagnostics and targeted treatment, addressing solid tumours and fibrotic conditions effectively.
By | 5 minutes of readingLutetium-177 EDTMP provides a cost-effective, accessible, and efficacious alternative for bone pain palliation in metastatic cancer patients.
Lutetium-177 EDTMP: A Cost-Effective Alternative for Bone Pain Palliation in Cancer Read Post »
By | 9 minutes of readingLutetium-177 Edotreotide revolutionises neuroendocrine tumour treatment through targeted radioligand therapy, enhancing precision and improving patient outcomes.
By | 10 minutes of readingLutetium-177 EB-PSMA-617 represents an innovative radioligand therapy optimising tumour retention and therapeutic outcomes in metastatic prostate cancer.
By | 10 minutes of readingLutetium-177 DTPA-Omburtamab offers hope in neuroblastoma treatment by precisely targeting B7-H3, delivering localised radiation while sparing healthy tissues.
By | 9 minutes of readingLutetium-177 DPI-4452 pioneers precision radiotheranostics, revolutionising treatment for CAIX-expressing solid tumours through targeted imaging, therapy, and personalised oncology care advancements.
By | 10 minutes of readingLutetium-177 DOTAZOL offers a dual-function approach, combining targeted radiotherapy and bone modulation, enhancing treatment for prostate cancer-related bone metastases.
By | 9 minutes of readingLutetium-177 DOTA-EB-TATE enhances neuroendocrine tumour therapy by improving tumour uptake, retention, and pharmacokinetics through albumin-binding Evans blue moieties.
Neuroendocrine Tumour Therapy: The Rise of Lutetium-177 DOTA-EB-TATE Read Post »
By | 10 minutes of readingLutetium-177 DOTA-EB-FAPi revolutionises oncology by enhancing precision targeting of fibroblast activation protein, improving tumour uptake, and expanding therapeutic applications.
Lutetium-177 DOTA-EB-FAPi: Pioneering a New Era in Precision Oncology and Beyond Read Post »
By | 7 minutes of readingRadiotheranostics in prostate cancer enables precise diagnosis and targeted treatment, improving patient outcomes significantly.
Radiotheranostics in Prostate Cancer: A New Frontier in Precision Treatment Read Post »
By | 4 minutes of readingLutetium-177 Debio 1124, a second-generation theranostic agent, selectively targets CCK2R-expressing tumours, offering precision radiotherapy and personalised oncology advancements.
By | 4 minutes of readingLutetium-177 CTT1403, an innovative PSMA-targeted therapy with irreversible phosphoramidate-based binding, shows remarkable efficacy in treating metastatic prostate cancer, enhancing tumour uptake, internalisation, and therapeutic precision.
Lutetium-177 CTT1403: A Therapeutic Breakthrough in Prostate Cancer Treatment Read Post »
By | 4 minutes of readingExploring Lutetium-177 AMTG highlights its innovative design, enhanced metabolic stability, and potential for effectively treating GRPR-positive prostate and breast tumours.
By | 4 minutes of readingThe rise and fall of Iodine-131 Tositumomab highlights challenges in balancing innovation, efficacy, infrastructure, and cost within radiopharmaceutical therapies.
The Rise and Fall of Iodine-131 Tositumomab: Bexxar’s Story Read Post »
By | 4 minutes of readingIodine-131 TM601, a synthetic radiolabelled peptide, targets tumour cells expressing Annexin A2, delivering therapeutic radiation and exhibiting anti-angiogenic properties effectively.
Iodine-131 TM601: Targeting Tumours with Radiolabelled Peptides Read Post »
By | 4 minutes of readingTLX101 is a revolutionary radiopharmaceutical targeting gliomas, offering dual imaging and therapy through tumour-selective uptake, enhancing treatment outcomes.
TLX101: A Pioneering Radiopharmaceutical for Glioma Diagnosis and Therapy Read Post »
By | 4 minutes of readingIodine-131 Sodium Iodide plays a pivotal role in diagnosing and treating thyroid diseases, including carcinomas, through targeted radiotherapy and imaging.
The Role of Iodine-131 Sodium Iodide in Thyroid Disease Diagnosis and Therapy Read Post »
By | 5 minutes of readingIodine-131 RPS-001, a radiolabelled small molecule targeting PSMA, shows promise in prostate cancer therapy through precision-directed beta radiation delivery.
Iodine-131 RPS-001: A Promising Radiolabelled Molecule in Prostate Cancer Therapy Read Post »
By | 4 minutes of readingIodine-131 Omburtamab offers targeted radiation therapy, significantly improving survival in neuroblastoma patients with CNS and leptomeningeal metastasis.
Iodine-131 Omburtamab: A Breakthrough in Neuroblastoma Therapy Read Post »
By | 6 minutes of readingIodine-131 naxitamab (¹³¹I-3F8) targets GD2-expressing cancers, offering precise radioimmunotherapy for neuroblastoma, melanoma, and small cell lung carcinoma.
The Role of Iodine-131 Naxitamab (¹³¹I-3F8) in Treating Neuroblastoma and Other Cancers Read Post »
By | 5 minutes of readingIodine-131 Metuximab (Licartin) selectively targets CD147 receptors, delivering beta radiation to hepatocellular carcinoma cells, improving treatment precision significantly.
Iodine-131 Metuximab (Licartin): A Radiolabelled Antibody for Hepatocarcinoma Treatment Read Post »
By | 4 minutes of readingIodine-131 Lipiodol has re-emerged as a promising therapy for hepatocellular carcinoma, particularly in non-resectable cases with portal vein thrombosis.
By | 7 minutes of readingCancer radiotheranostics combines targeted radiotherapy and diagnostic imaging to provide personalised, precise, and effective cancer treatment.
Cancer Radiotheranostics: The Future of Targeted Cancer Therapy Read Post »
By | 4 minutes of readingIodine-131 Iopofosine selectively delivers cytotoxic radiation to malignant cells by targeting the PI3K/Akt pathway, offering promising cancer therapy advancements.
Iodine-131 Iopofosine: A Novel Radiolabelled Alkyl Phosphocholine for Cancer Therapy Read Post »
By | 8 minutes of readingIodine-131 Iobenguane revolutionises neuroendocrine tumour management by offering targeted imaging and therapy, significantly improving diagnosis, treatment, and patient outcomes.
By | 8 minutes of readingRadiotheranostic treatments combine diagnostic imaging with targeted radiopharmaceutical therapy, providing personalised cancer care with enhanced precision and effectiveness.
Radiotheranostic Treatments: A Guide to Types and Their Clinical Applications Read Post »
By | 13 minutes of readingAlpha particles provide precise cancer treatment by delivering high-energy radiation, targeting tumour cells while sparing healthy tissue.
The Role of Alpha Particles in Radiotheranostics Read Post »
By | 3 minutes of readingIodine-131 ICF01012, targeting melanin receptors, shows promise in the fight against metastasised melanomas, heralding a new era in treatment.
By | 3 minutes of readingIodine-131 chTNT, aiming to revolutionise oncology, shows promise in targeting and eradicating tumour cells with precision.
Exploring Iodine-131 chTNT: A Beacon of Hope in Cancer Treatment Read Post »
By | 3 minutes of readingIodine-131 CAM-H2 heralds a new era in oncology, offering hope through precise targeting of HER2-expressing cancers with minimal side effects.
Exploring Iodine-131 CAM-H2 for Treating HER2-Expressing Cancers Read Post »
By | 13 minutes of readingRadiotheranostics offers a precise, personalised approach to cancer treatment by combining diagnostic imaging with targeted therapy.
The Future of Radiotheranostics: A New Frontier in Precision Medicine Read Post »
By | 3 minutes of readingIodine-131 BA52, a melanin-binding therapeutic, offers new hope for patients with melanin-positive malignant melanomas.
Exploring Iodine-131 BA52: A Novel Melanin-Targeted Therapy for Malignant Melanomas Read Post »
By | 3 minutes of readingTargeting Blood Cancers: The Role of Iodine-131 Apamistamab in Revolutionising Treatment for AML and Beyond.
The Role of Iodine-131 Apamistamab for Acute Myeloid Leukaemia Read Post »
By | 3 minutes of readingIodine-131 Monoclonal Antibody 81C6 specifically targets glioma cells by honing in on the tenascin protein.
Iodine-131 Monoclonal Antibody 81C6 Targets Glioma Cells Read Post »
By | 3 minutes of readingHolmium-166 Phytate, initially developed for chronic synovitis, has shown significant promise in phase I/II clinical trials.
Holmium-166 Phytate Offers a Promising Treatment Option for Chronic Synovitis Read Post »
By | 3 minutes of readingHolmium-166 Chitosan, a groundbreaking radiopharmaceutical, offers new hope in treating hepatocellular carcinoma with targeted therapy.
Holmium-166 Chitosan in Radiopharmaceutical Cancer Treatment Read Post »
By | 3 minutes of readingHolmium-166 microspheres, by delivering localized radiation, significantly enhance the therapeutic approach to inoperable liver cancer treatment.
The Role and Impact of Holmium-166 Microspheres in Brachytherapy Read Post »
By | 3 minutes of readingCopper-67 SARTATE emerges as a groundbreaking radiopharmaceutical in targeted cancer therapy, showcasing promising clinical trial results.
Unlocking the Potential of Copper-67 SARTATE in Targeted Radiopharmaceutical Therapy Read Post »
By | 3 minutes of readingCopper-67 SARbisPSMA offers new hope in targeting and treating prostate cancer with precision and effectiveness.
Copper-67 SARbisPSMA New Frontier in Prostate Cancer Treatment Read Post »
By | 19 minutes of readingThe article explores the theranostic applications of Terbium radionuclides, highlighting their diagnostic and therapeutic potential in nuclear medicine.
Terbium Radionuclides for Theranostic Applications in Nuclear Medicine Read Post »
By | 3 minutes of readingCopper-64 Diasparagine offers a promising breakthrough in targeting and treating aggressive brain tumours like glioblastoma.
By | 3 minutes of reading213Bi-Lintuzumab demonstrated efficacy in AML treatment, offering a targeted approach with manageable side effects, yet development paused.
Bismuth-213 Lintuzumab: A Promising Treatment for Acute Myeloid Leukaemia Read Post »
By | 3 minutes of reading213Bi-DOTATOC offers potent, targeted alpha therapy for tumours, advancing treatment with precision and reduced systemic toxicity.
Bismuth-213 DOTATOC: A Promising Alpha-Labelled Analogue for Tumour Therapy Read Post »
By | 3 minutes of reading211At-MX35-F(ab’)2 shows promise in treating ovarian cancer through targeted therapy in ongoing clinical trials.
The Potential of Astatine-211-MX35-F(ab’)2 in Ovarian Cancer Treatment Read Post »
By | 3 minutes of readingThe innovative 211At-MABG targets rare tumours like malignant pheochromocytoma and paragangliomas, promising a new era in treatment.
Astatine-211 MABG in Malignant Pheochromocytoma and Paragangliomas Read Post »
By | 2 minutes of readingNeuroblastoma Targeting Agents offer innovative diagnostic and therapeutic options, revolutionizing treatment with precise targeting and efficacy.
Neuroblastoma Targeting Agents: An Insight into Diagnostic and Therapeutic Advances Read Post »
By | 2 minutes of readingTechnetium-99m and Radium-223 are pivotal in managing bone metastases, enhancing both diagnostic accuracy and therapeutic efficacy.
By | 3 minutes of readingGallium-68 and Lutetium-177 labelled Girentuximab mark a breakthrough in diagnosing and treating hepatocellular carcinoma.
Targeting Hepatocellular Carcinoma: The Emerging Role of Girentuximab Read Post »
By | 3 minutes of readingUtilising CXCR4 targeting agents with labelled ligands marks a breakthrough in treating haematological malignancies effectively.
CXCR4 Targeting Agents for Haematologic Malignancies Read Post »
By | 3 minutes of readingFolate Receptor Targeting Agents revolutionise cancer diagnosis and treatment with Fluorine-18 and Rhenium-188 labelling.
Folate Receptor Targeting Agents: Pioneering Progress in Cancer Diagnosis and Therapy Read Post »
By | 3 minutes of readingEstrogen receptor targeting agents, including Fluorine-18 and Iodine-131 analogues, revolutionise breast cancer diagnostics, therapeutics, and personalised patient management.
Estrogen Receptor Targeting Agents: Transforming Breast Cancer Diagnosis and Treatment Read Post »
By | 3 minutes of readingFAPI revolutionises oncology with precise Gallium-68 diagnostics and targeted Lutetium-177 therapy for cancer.
By | 3 minutes of readingSomatostatin Receptor Targeting Agents offer groundbreaking diagnostic and therapeutic solutions for neuroendocrine tumour management and care.
Somatostatin Receptor Targeting Agents: Revolutionising Neuroendocrine Tumour Management Read Post »
By | 5 minutes of readingPSMA targeting agents revolutionise prostate cancer care with precise diagnostics and targeted therapeutic approaches.
By | 3 minutes of reading211At-BC8-B10, targeting CD45 in leukemia, combines BC8 antibody with Astatine-211, showing promising clinical trials.
Astatine-211 BC8-B10: A Promising Radioimmunoconjugate for Leukaemia Treatment Read Post »
By | 3 minutes of readingAstatine-211 in radiotheranostics offers targeted, effective cancer treatment, but faces production and safety challenges.
Astatine-211 Radiotheranostics: A New Era in Cancer Treatment Read Post »
By | 3 minutes of reading211At-81C6-mAb, targeting tenascin in brain tumours, shows extended survival but needs further funding for development.
Astatine-211 81C6-mAb: A Breakthrough in Brain Tumour Treatment with Alpha Radiation Read Post »
By | 3 minutes of reading225Ac-RYZ101 offers promising GEP-NET treatment, targeting tumours with alpha particles via somatostatin receptor-specific edotreotate.
By | 4 minutes of reading225Ac-Rosopatamab, targeting metastatic prostate cancer, combines monoclonal antibodies with alpha radiation, showing promise in early trials.
Actinium-225 Rosopatamab: A Breakthrough in Metastatic Prostate Cancer Treatment Read Post »
By | 4 minutes of reading225Ac-PSMA-617 revolutionises prostate cancer treatment, offering targeted, effective therapy with promising clinical trial results.
Actinium-225 PSMA-617: Revolutionising Prostate Cancer Treatment Read Post »
By | 3 minutes of reading225Ac-MTI-201, targeting MC1R, offers groundbreaking, targeted treatment for uveal melanoma with minimal side effects.
Actinium-225 MTI-201: A Promising New Agent in Uveal Melanoma Treatment Read Post »
By | 3 minutes of reading225Ac-Lintuzumab, targeting CD33, shows promise in AML treatment with potential expansion to other cancers.
Actinium-225 Lintuzumab: A Breakthrough in Acute Myeloid Leukaemia Treatment Read Post »
By | 3 minutes of reading225Ac-FPI-2265, targeting PSMA, shows promise in treating advanced prostate cancer in the TATCIST clinical trial.
By | 4 minutes of reading225Ac-FPI-2068 and 111In-FPI-2107 represent a major advancement in targeted alpha therapy for various solid tumours.
By | 4 minutes of reading225Ac-FPI-2059 targets NTSR1 in cancer cells, offering a novel approach in pancreatic cancer treatment.
Actinium-225 FPI-2059: Targeted Alpha Therapy in Oncology through NTSR1 Targeting Read Post »
By | 4 minutes of reading225Ac-FPI-1434 advances in clinical trials, targeting IGF-1R in chemo-resistant solid tumors with promising results.
By | 3 minutes of reading225Ac-DOTAZOL enhances 177Lu-radiotherapy in bone diseases, particularly effective in prostate cancer, as shown in preclinical studies.
By | 5 minutes of reading225Ac-DOTATOC advances GEP-NET treatment, offering targeted, effective therapy for patients resistant to traditional methods.
By | 5 minutes of reading225Ac-DOTA-YS5 targets CD46 in prostate cancer, promising precision and effectiveness in therapy.
By | 5 minutes of readingThis article examines the cancer risks associated with radionuclide administration in medical treatments and strategies for mitigation.
Assessing the Cancer Risk in Patients Administered Radionuclides Read Post »
By | 4 minutes of reading225Ac-DOTA-SP, a breakthrough in targeted alpha therapy, offers precise cancer treatment with minimal side effects, revolutionising oncological approaches.
By | 6 minutes of readingRadionuclide production, encompassing reactor-based, cyclotron, and generator methods, is essential for medical, industrial, and research applications worldwide.
Radionuclide Production: Methods and Applications Read Post »
By | 5 minutes of readingDosimetry in radionuclide therapy plays a crucial role in optimising treatment effectiveness and ensuring patient safety and well-being.
Precision in Treatment: The Role of Dosimetry in Radionuclide Therapy Read Post »
By | 5 minutes of readingRadiotheranostic Pairs combine diagnostic imaging with targeted radiotherapy, revolutionising personalised cancer treatment through enhanced precision and efficacy.
Radiotheranostic Pairs: Bridging Diagnostics and Therapeutics in Cancer Read Post »
By | 11 minutes of readingRadiotheranostics combines diagnostic imaging and targeted radiotherapy using alpha, beta, gamma, and positron particles for precision treatment.
Particles in Radiotheranostics for Precision Medicine Read Post »
By | 5 minutes of readingRadiotheranostics combines diagnostic imaging and targeted radiotherapy, using radiopharmaceuticals for personalised, precise cancer treatment and improved outcomes.
What is Radiotheranostics? The Future of Personalised Cancer Diagnosis Read Post »
By | 23 minutes of readingTargeted Alpha Radionuclide Therapy precisely delivers potent alpha particles to tumors, maximising efficacy while sparing healthy tissues.
The Role of Targeted Alpha Radionuclide Therapy in Modern Oncology Read Post »
By | 3 minutes of readingWorld Theranostics Day honours Dr. Hertz’s groundbreaking radioiodine therapy, transforming disease treatment globally since 1941.
Celebrating World Theranostics Day Honoring Saul Hertz Read Post »
By | 15 minutes of readingTheragnomics melds theranostics and radiomics, promising targeted cancer therapies with improved outcomes through precision diagnostics and treatment adaptation.
Combining Theranostics and Radiomics: The Emergence of Theragnomics Read Post »
By | 18 minutes of readingRadiotheranostics merges diagnostics and therapy, offering targeted cancer treatment amidst challenges like high costs and need for specialised facilities.
Revolutionising Cancer Care: The Promise and Challenges of Radiotheranostics Read Post »
By | 20 minutes of readingThorium-227 emerges in nuclear medicine, revolutionizing cancer treatment through precise, effective radiotheranostic and therapeutic applications.
The Breakthrough Role of Thorium-227 in Theranostic Radiopharmaceuticals Read Post »
By | 8 minutes of readingTheranostics is a cutting-edge approach that integrates diagnosis and therapy, enabling personalised and precise disease management.
Personalised Theranostics for Cancer: A New Era in Precision Medicine Read Post »
By | 12 minutes of readingTargeted radionuclide therapy was first used to treat cancer for an ‘over-active’ thyroid using radioactive iodine-131 seeds.
Targeted radionuclide therapy (TAT) towards precision cancer treatment Read Post »
By | 6 minutes of readingThe nuclear medicine imaging approach is to use theranostics for example Zevalin to establish tools for specific molecular targeting.
Radiolabelled Theranostic Agents for Targeted Cancer Diagnosis and Treatment Read Post »
